Pharmaceutical and Cosmetics Archives

Printed Drug Labeling Requirements Remain in Effect

Drug & Biologic Product Submissions, Drug Label Research, Life Sciences, Pharmaceutical and Cosmetics

Understand how the US government shutdown affects FDA operations and how LexisNexis supports healthcare readiness.

30 Days Into the U.S. Government Shutdown: What It Means for the FDA and for You

Life Sciences, Medical Device Safety and Quality, Medical Devices, Pharmaceutical and Cosmetics, Unique Device Identification

Understand how the US government shutdown affects FDA operations and how LexisNexis supports healthcare readiness.

How a Government Shutdown Impacts the FDA and Healthcare Industry

Medical Device Safety and Quality, Medical Devices, Pharmaceutical and Cosmetics

A government shutdown forces the FDA to scale back operations, delaying new drug and device approvals and slowing healthcare innovation. Learn what continues, what pauses, and why prolonged disruptions matter for patients and providers

Pharmaceutical Industry Top Innovators

Drug & Biologic Product Submissions, Drug Label Research, Medical Devices, Pharmaceutical and Cosmetics, Unique Device Identification

Explore the key Pharmaceutical Innovators revealed in the latest Innovation Momentum report and their impact on the industry.

FHIR and the Future of Labeling

Drug & Biologic Product Submissions, Drug Label Research, Life Sciences, Medical Devices, Pharmaceutical and Cosmetics, Unique Device Identification

Learn how manufacturers can adopt FHIR to modernize labeling, enhance traceability, and meet evolving regulatory expectations.

Regulatory Survival Guide: FAQs Every Drug and Medical Device Manufacturer Should Know

Drug Label Research, Medical Device Safety and Quality, Medical Devices, Pharmaceutical and Cosmetics, Unique Device Identification

Navigating drug and device regulations isn’t optional—it’s mission-critical. This Regulatory Survival Guide breaks down the complexities of global compliance, from FDA and EU MDR to Health Canada, UDI, and MoCRA. Whether you’re managing submissions or facing upcoming deadlines, use this FAQ to decode key terms, avoid costly risks, and stay ahead with expert-backed solutions like Compliance-as-a-Service (CaaS).

Reflecting on RAPS Euro Convergence 2025: Regulatory Innovation in Motion

Drug & Biologic Product Submissions, Life Sciences, Medical Device Safety and Quality, Medical Devices, Pharmaceutical and Cosmetics

Global supply chain shifts can jeopardize regulatory labeling. Learn how LexisNexis Reed Tech helps manufacturers stay compliant through agile, localized labeling solutions.

Shifting Manufacturing? Don’t Let Tariffs Disrupt Your Labeling Compliance

Drug & Biologic Product Submissions, Life Sciences, Pharmaceutical and Cosmetics

Global supply chain shifts can jeopardize regulatory labeling. Learn how LexisNexis Reed Tech helps manufacturers stay compliant through agile, localized labeling solutions.

ESG NextGen Is Coming: Key Milestones, Blackout Dates & What You Need to Know

Drug & Biologic Product Submissions, Life Sciences, Medical Device Safety and Quality, Medical Devices, Pharmaceutical and Cosmetics

As part of ongoing enhancements to streamline data exchange and compliance processes, the ESG NextGen platform is preparing to go live this spring. We’re sharing a quick overview of the key milestones and what they mean for you especially as we approach the submission blackout period from April 12 to April 14, 2025.

Knowledge Center